Nevertheless, some preclinical PPGL and neuroblastoma models show a lack of efficiency of these inhibitors (1, 63, 132), which is also in line with some clinical data from other HIF2α-dependent tumor entities that show resistance towards the available HIF2α inhibitors (133, 134). The gene discussed is EPAS1; the disease is neoplasm.